The U.S. Food and Drug Administration approved Foundayo (orforglipron) on April 1, 2026, for adults with obesity, or overweight with at least one weight-related medical condition, used alongside a reduced-calorie diet and increased physical activity. It is the first oral small-molecule (non-peptide) GLP-1 receptor agonist cleared for chronic weight management. Unlike oral semaglutide (the Wegovy pill), which must be taken in the morning on an empty stomach with no more than four ounces of water, Foundayo can be taken any time of day without food or water restrictions.
The approval rested primarily on the phase 3 ATTAIN-1 trial, published in the New England Journal of Medicine (2025;393:1796-1806) and presented at EASD 2025. In adults with obesity or overweight without type 2 diabetes, the highest dose (36 mg once daily) produced an average weight reduction of 12.4% (27.3 lb) at 72 weeks among participants who stayed on treatment, versus 0.9% (2.2 lb) with placebo; counting all randomized participants regardless of adherence, the reduction was 11.1% versus 2.1%. A companion trial in people with type 2 diabetes, ATTAIN-2, reported roughly 10% weight loss and A1C reductions near 1.8% at the top dose.
Because orforglipron is a small molecule rather than a peptide, it can be manufactured by conventional chemical synthesis and does not require the injection or the fasted, low-water dosing window of peptide-based oral GLP-1 drugs. That distinction is the drug's central selling point and the reason it drew attention through its development.
The label carries a boxed warning for the risk of thyroid C-cell tumors, seen in rodent studies, and the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma, those with Multiple Endocrine Neoplasia syndrome type 2, and anyone with a serious hypersensitivity to orforglipron. The most common adverse reactions are gastrointestinal — nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain — consistent with the injectable GLP-1 class and generally mild to moderate.
The FDA cleared Foundayo under the Commissioner's National Priority Voucher pilot program, and Lilly described it as the fastest new molecular entity approval since 2002. The approval updates the site's earlier ATTAIN-1 coverage, which was written before the drug was authorized.